therapeutically beneficial on ICH outcomes, as shown by measures of hematoma volume, cerebral blood flow / perfusion result and functional neurological assessments.

Summary

In one aspect, the present disclosure provides a use of cells in the manufacture of a medicament for treating intracerebral hemorrhage in a subject, wherein said cells are multipotent adult progenitor cells that are not embryonic stem cells, not embryonic germ cells, and not germ cells, can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal embryonic lineages, and are allogeneic or xenogeneic to the subject.

In another aspect, the present disclosure provides a use of cells in the manufacture of a medicament for treating intracerebral hemorrhage in a subject, wherein said cells are multipotent adult progenitor cells that are not embryonic stem cells, not embryonic germ cells, and not germ cells, express telomerase and are allogeneic or xenogeneic to the subject.

In yet another aspect, the present disclosure provides a use of cells in the manufacture of a medicament for treating intracerebral hemorrhage in a subject, wherein the cells are multipotent adult progenitor cells that are not embryonic stem cells, not embryonic germ cells, and not germ cells, are positive for oct3/4 and are allogeneic or xenogeneic to the subject.

In one aspect, the present disclosure provides a use of cells in the manufacture of a medicament for treating intracerebral hemorrhage in a subject, wherein the cells are multipotent adult progenitor cells that are not embryonic stem cells, not embryonic germ cells, and not germ cells, undergone at least 40 cell doublings in culture prior to their use, and are allogeneic or xenogeneic to the subject.

II

A few of the many embodiments encompassed by the present description are summarized in the following numbered paragraphs. The numbered paragraphs are self-referential. In particular, the phase "in accordance with any of the foregoing or the following" used in these paragraphs refers to the other paragraphs. The phrase means, in the following paragraphs, embodiments herein disclosed include both the subject matter described in the individual paragraphs taken alone and the subject matter described by the paragraphs taken in combination. In this regard, it is explicitly applicant's purpose in setting forth the following paragraphs to describe various aspects and embodiments particularly by the paragraphs taken alone or in any combination. That is, the paragraphs are a compact way of setting out and providing explicit written description of all the embodiments encompassed by them individually and in any combination with one another. Applicant specifically reserves the right at any time to claim any subject matter set out in any of the following paragraphs, alone or together with any other subject matter of any one or more of the other paragraphs, including any combination of any values therein set forth, taken alone or in any combination with any other value therein set forth. Should it be required, applicant specifically reserves the right to set forth all of the combinations herein set forth in full in this application or in any successor applications having benefit of this application.

p1. A method of treating intracerebral hemorrhage in a subject, comprising administering to a subject in need thereof multipotent adult progenitor cells that are not embryonic stem cells, not embryonic germ cells, and not germ cells, can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal embryonic lineages, and are allogeneic or xenogeneic to the subject.

What is claimed is:

1. Use of cells in the manufacture of a medicament for treating intracerebral hemorrhage in a subject, wherein said cells are multipotent adult progenitor cells that are not embryonic stem cells, not embryonic germ cells, and not germ cells, can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal embryonic lineages, and are allogeneic or xenogeneic to the subject.

2. Use of cells in the manufacture of a medicament for treating intracerebral hemorrhage in a subject, wherein said cells are multipotent adult progenitor cells that are not embryonic stem cells, not embryonic germ cells, and not germ cells, express telomerase and are allogeneic or xenogeneic to the subject.

3. Use of cells in the manufacture of a medicament for treating intracerebral hemorrhage in a subject, wherein the cells are multipotent adult progenitor cells that are not embryonic stem cells, not embryonic germ cells, and not germ cells, are positive for oct3/4 and are allogeneic or xenogeneic to the subject.

4. Use of cells in the manufacture of a medicament for treating intracerebral hemorrhage in a subject, wherein the cells are multipotent adult progenitor cells that are not embryonic stem cells, not embryonic germ cells, and not germ cells, undergone at least 40 cell doublings in culture prior to their use, and are allogeneic or xenogeneic to the subject.

5. The use according to any one of claims 2-4, wherein said cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal embryonic lineages.

6. The use according to any one of claims 3-4, wherein said cells express telomerase.

7. The use according to 3, wherein said cells have undergone at least 40 doublings in culture prior to their use. ~~B~~

8. The use according to claim 1, wherein said cells express telomerase and are positive for oct3/4.

9. The use according to claim 1, wherein said cells express telomerase and have undergone at least 40 doublings in culture prior to their use.

10. The use according to claim 1, wherein said cells are positive for oct3/4 and have undergone at least 40 doublings in culture prior to their use~~.~~.

11. The use according to claim 1, wherein said cells express telomerase, are positive for oct3/4, and have undergone at least 40 doublings in culture prior to their use.

12. The use according to any one of claims 1-11, wherein said cells have a normal karyotype.

13. The use according to any one of claims 1-12, wherein said cells are not tumorigenic.

14. The use according to any one of claims 1-13, wherein said cells are not immunogenic in said subject.

15. The use according to any one of claims 1-14, wherein said cells can differentiate into at least one cell type of each of the endodermal, ectodermal, and mesodermal embryonic lineages.

16. The use according to any one of claims 1-15, wherein said cells are mammalian cells.

17. The use according to any one of claims 1-16, wherein said cells are human cells.

18. The use according to any one of claims 1-17, wherein said cells are derived from cells isolated from any one of placental tissue, umbilical cord tissue, umbilical cord blood, bone marrow, blood, spleen tissue, thymus tissue, spinal cord tissue, adipose tissue, and liver tissue.

19. The use according to any one of claims 1-18, wherein said cells are derived from bone marrow.

20. The use according to any one of claims 1-19, wherein the subject is a human.

21. The use according to any one of claims 1-20, wherein one or more doses of 10^4 to 10^8 of said cells per kilogram of the subject's mass are to be administered~~used~~.

22. The use according to any one of claims 1-21, wherein one or more doses of 10^6 to 5×10^7 of said cells per kilogram of the subject's mass are to be administered~~used~~.

23. The use according to any one of claims 1-22, wherein an anti-microbial agent, an anti-fungal agent, an anti-viral agent or a combination thereof is to be administered~~used~~ concurrently.

24. The use according to any one of claims 1-23, wherein said cells are in a formulation comprising one or more other pharmaceutically active agents.

25. The use according to any one of claims 1-24, wherein said cells are to be administered by a parenteral method, an intravenous method or a stereotactic method.

26. The use according to any one of claims 1-25, wherein said cells are to be administered by an intravenous method.

27. The use according to any one of claims 1-26, wherein said medicament is to be used without use of an adjunctive immunosuppressant.